TBK1 and COVID-19: Therefore, given IDX’s unique mechanism-of-action in restricting harmful TBK1/IKKε signalling, we anticipate that our findings will be the starting point in the therapeutic development of IDX, or its derivatives, to limit the harmful TBK1/IKKε signalling seen in viral-mediated hyper-inflammation, including COVID-19 immunopathology.